In race for cancer therapy, a Chinese biotech surges 500%
Bloomberg In the global race to use human immune cells to fight cancers, a little-known Chinese firm called GenScript Biotech Corp. is emerging as one of the biggest stock gainers. Among the first Chinese developers of so-called CAR-T cancer therapies, GenScript’s shares have risen more than sixfold since June, when it reported positive results from early studies in 35 patients ...
Read More »